HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Stenman, U.-H. Search for Related Content PubMed PubMed Citation Articles by Stenman, U.-H. Related Collections Proteomics and Protein Markers Endocrinology and Metabolism

Standardization as a Private Enterprise

Department of Clinical Chemistry, Helsinki University Hospital, Biomedicum Room 424, FIN-00029 Helsinki, Finland, E-mail ulf-hakan.stenman@hus.fi

The first 20% of the full text of this article appears below.

Standardization of analytical methods in clinical chemistry is important because it facilitates interpretation of laboratory results. Many chemical determinations are now well standardized, but this is less common with immunoassays. Standardization requires availability of a primary standard and a reference method. Although standards are available for most clinically important analytes, reference methods for immunoassays are available only for haptens (1). The study of Haese et al. (2) in this issue aims at standardization of assays for human kallikrein 2 (hK2); it highlights many of the problems associated with standardization of sensitive immunoassays and with the use of recombinant proteins as standards.

hK2 is a potentially important marker for prostate cancer, the most promising application being evaluation of tumor aggressiveness. Most prostate cancers grow slowly, with average tumor-doubling time being 2–4 years, but some tumors grow aggressively. Moreover, it is important to know whether a slightly increased prostate-specific antigen (PSA) value is caused by benign prostatic disease or by a cancer and, if so, whether this cancer needs to be cured. On the tissue level, PSA expression decreases with increasing tumor grade (and aggressiveness), whereas hK2 expression is constant or less affected (3). Several . . . [Full Text of this Article]